---
schema_version: "secwatch.filing_event.v1"
accession: "0001606498-22-000073"
form_type: "8-K"
ticker: "AVNS"
cik: "0001606498"
company_name: "AVANOS MEDICAL, INC."
filed_at: "2022-10-11T23:59:59+00:00"
generated_at: "2026-06-23T04:24:29.846439+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Director Maria Sainz to resign from Avanos Board effective Jan 1, 2023

## Summary
- Director Maria Sainz notified Avanos of resignation from Board, effective January 1, 2023.
- Resignation is not due to any disagreement with the Company's operations, policies, or practices.
- Ticker: AVNS; effective date allows for orderly transition.

## SEC filing metadata
- accession: 0001606498-22-000073
- form_type: 8-K
- ticker: AVNS
- cik: 0001606498
- company_name: AVANOS MEDICAL, INC.
- filed_at: 2022-10-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1606498/000160649822000073/0001606498-22-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1606498/000160649822000073/avns-20221007.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001606498-22-000073
- JSON: https://secwatch.observer/filing/0001606498-22-000073.json
- Plain text: https://secwatch.observer/filing/0001606498-22-000073.txt

## Key facts
- Executive change
  Maria Sainz resigned as Director at AVANOS MEDICAL, INC..
  - Action: resigned
  - Role: Director
  source text: On October 7, 2022, Maria Sainz, a member of the Board of Directors (the “Board”) of Avanos Medical, Inc. (the “Company”), notified the Company of her intention to resign from the Board, effective January 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1606498/000160649822000073/0001606498-22-000073-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.